Verification of the cardioprotective effect of ARNI on hemodialysis patients with heart disease

Verification of the cardioprotective effect of ARNI on hemodialysis patients with heart disease - Verification of the cardioprotective effect of ARNI on hemodialysis patients with heart disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052905

Enrollment

300

Registered

2023-11-27

Start date

2023-11-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients with diagnosed cardiac disease

Interventions

Start with ARNI 50mg, 2 tablets a day after breakfast and dinner, and increase to a maximum of 400mg depending on tolerability for 1 year. ARNI non-administration group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatient maintenance dialysis patients with heart disease who are attending our hospital as an outpatient and have consented to take ARNI orally.

Exclusion criteria

Exclusion criteria: Patients who have difficulty undergoing dialysis due to low blood pressure, patients with dementia, and patients who were unable to consent.

Design outcomes

Primary

Measure	Time frame
Compare changes in cardiac function in the ARNI administration group before and 12 months after initiation of ARNI with the control group.	—

Secondary

Measure	Time frame
Changes in NTproBNP, HANP, and blood pressure before starting ARNI, 1 month, 3 months, 6 months, and 12 months after starting ARNI	—

Countries

Japan

Contacts

Public ContactYuko Fujiwara

Inoue Hospital Medical department

fujiwara.yuuko@aijinkai-group.com0663858651

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026